Clinical Trials

Analysts expect GW Pharmaceuticals plc (NASDAQ:GWPH) to report $-2.99 EPS on February, 4.They anticipate $0.56 EPS change or 23.05% from last quarter’s $-2.43 EPS. After having $-2.76 EPS previously, GW Pharmaceuticals plc’s analysts see 8.33% EPS growth. The stock increased 0.85% or $1.15 during the last trading session, reaching $135.65. About 28,512 shares traded. GW […]

by

The cannabidiol marketplace is likely to witness significant RD investment in the pharmaceutical industry as a broad-spectrum pharmaceutical therapeutics. Multiple scientific studies have shown promising results of cannabidiol for its potential in the treatment of a number of diseases. Following which the cannabidiol market is marked by a considerable cannabidiol therapeutics getting FDA approval or […]

by

Cannabis-based experimental therapies currently under research, in particular Epidiolex, show significant promise to treat therapy-resistant epilepsy, including Dravet syndrome, according to a recent review. The report “Investigational cannabinoids in seizure disorders, what have we learned thus far?” published in the journal Expert Opinion in Investigational Drugs, provides an overview on the recent advances of investigational cannabinoids (cannabis-derived […]

by

Recent studies at Colorado State University’s James L. Voss Veterinary Teaching Hospital, overseen by Dr. Stephanie McGrath, have found the use of cannabidiol to be beneficial for dogs with epilepsy. Atticus, a 3-year old St. Bernard, is enrolled in a CBD oil clinical trial at the James L. Voss Veterinary Teaching Hospital. Atticus is in […]

by

On Monday, GW Pharmaceuticals made history by becoming the first company to ever win Food and Drug Administration (FDA) approval for a marijuana plant-based prescription drug, dubbed Epidiolex. The approval was widely expected after a panel of FDA advisers unanimously recommended its regulatory clearance back in April; still, it was a milestone on the federal […]

by

Essex Financial Services Inc increased Compass Diversifiedhldgs (CODI) stake by 99932.27% reported in 2018Q3 SEC filing. Essex Financial Services Inc acquired 656,555 shares as Compass Diversifiedhldgs (CODI)’s stock declined 18.25%. The Essex Financial Services Inc holds 657,212 shares with $11.93M value, up from 657 last quarter. Compass Diversifiedhldgs now has $896.70M valuation. The stock increased […]

by

New England Research Management Inc decreased Dycom Industries (DY) stake by 62.11% reported in 2018Q3 SEC filing. New England Research Management Inc sold 10,325 shares as Dycom Industries (DY)’s stock declined 32.67%. The New England Research Management Inc holds 6,300 shares with $533,000 value, down from 16,625 last quarter. Dycom Industries now has $1.82B valuation. […]

by

LINCOLN, NE – Medical marijuana continues to be a key issue facing the Nebraska Legislature this session. In December, Nebraska senators Adam Morfeld and Anna Wishart created the Nebraskans for Sensible Marijuana laws committee. This group is aiming to put a proposed constitutional amendment before voters on the 2020 ballot. Sen. Wishart has already introduced another […]

by

JERUSALEM, Dec. 19, 2018 /PRNewswire/ —  Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Fellow Shareholders: 2018 was a transitional year for Intec Pharma, with advances […]

by

NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the launch of a new corporate website and release of its most recent management presentation, which outlines the Company’s strategic initiatives including the prioritization of its clinical development program […]

by

Kalytera Therapeutics (OTCQB:KALTF -3%) announces preliminary data from a Phase 2 clinical trial evaluating its oral cannabidiol for the prevention of graft versus host disease (GvHD) following bone marrow transplant. Interim results from 12 treated patients showed no cases of severe (grade 3) or life-threatening (grade 4) acute GvHD. One patient developed moderate (grade 2) […]

by